Cipla Limited (CIPLA) — Announcement Announcement
📢 Key Event
USFDA classifies Cipla's Goa facility inspection as Voluntary Action Indicated
💡 Investor Takeaway
The VAI classification indicates no significant regulatory setbacks, supporting confidence in Cipla's manufacturing operations.
Cipla announced that the USFDA classified its recent cGMP and Pre-Approval Inspection at the Verna, Goa facility as Voluntary Action Indicated (VAI), confirming no major compliance breaches. The filing notes the inspection occurred from 6 to 17 April 2026 and was communicated by the FDA on 10 June 2026. This outcome supports ongoing product approvals and supply continuity, reassuring investors of stable manufacturing compliance.
📄 View Original Announcement (PDF)
About Cipla Limited (CIPLA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,15,682.55 Cr
P/E: 25.4
ROE: 14.6%
ROCE: 19.4%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.